The passage of the Family Smoking Prevention and Tobacco Control Act in June 2009 empowers the Food and Drug Administration to regulate tobacco products. In the FSPTC, there is significant focus on tobacco products and its evaluation. One critical component of this product evaluation process is human clinical trials. These trials will inform the regulatory agency about the uptake of the product, how the product is used, the extent of toxicant exposure and possible health risk associated with this pattern of use. To date, no study has examined the best experimental methods to provide the information that is necessary to make a sound scientifically-based decision about a tobacco product (e.g., modified risk tobacco products) or any regulations imposed on tobacco products (e.g., performance standards) that assures no public harm will result based on this decision. The goals of this research project are to test a clinical trial method for assessing tobacco products and also address some methodological gaps so that guidance can be provided to the FDA and other international regulatory agencies on the best measures and methods for the evaluation of tobacco products. This trial is a between-subject, parallel-arm design in which subjects are randomized to one of the five experimental conditions, with different instructional sets, for a period of 12-weeks. The product chosen for testing is an oral tobacco product. Camel Snus. The instructional sets include: complete substitution vs. partial substitution for cigarettes by ad libitum use vs. specific instruction for snus use. A control group of continuing smokers will also be included in the design. The primary outcome measures include biomarkers of toxicant exposure and effect and subjective responses to the product. The overall goal for this P01 is to assimilate the results from this Project with the results from the other P01 Projects to determine consistency of findings across studies, predicitive validity of measures, and to determine if the proposed """"""""pre-market"""""""" studies can be used to determine risks and benefits of introducing a tobacco product into the market.

Public Health Relevance

With the new legislation that empowers the Food and Drug Administration to regulate tobacco products, clinical trials of tobacco products are going to be essential in making regulatory decisions. This research project examines a clinical trial method for testing a tobacco product and addresses some of the existing methodological gaps in this area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19CA157345-01A1
Application #
8310410
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (J1))
Project Start
2012-09-01
Project End
2017-08-31
Budget Start
2012-09-20
Budget End
2013-08-31
Support Year
1
Fiscal Year
2012
Total Cost
$870,270
Indirect Cost
$117,987
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Adkison, Sarah E; Rees, Vaughan W; Bansal-Travers, Maansi et al. (2016) Psychometric Characteristics of the Brief Wisconsin Inventory of Smoking Dependence Motives Among a Nonclinical Sample of Smokers. Nicotine Tob Res 18:470-6
Hatsukami, Dorothy K; Vogel, R I; Severson, Herb H et al. (2016) Perceived Health Risks of Snus and Medicinal Nicotine Products. Nicotine Tob Res 18:794-800
Bickel, Warren K; Snider, Sarah E; Quisenberry, Amanda J et al. (2016) Competing neurobehavioral decision systems theory of cocaine addiction: From mechanisms to therapeutic opportunities. Prog Brain Res 223:269-93
Bickel, Warren K; Moody, Lara; Higgins, Stephen T (2016) Some current dimensions of the behavioral economics of health-related behavior change. Prev Med 92:16-23
Wilson, A George; Franck, Christopher T; Koffarnus, Mikhail N et al. (2016) Behavioral Economics of Cigarette Purchase Tasks: Within-Subject Comparison of Real, Potentially Real, and Hypothetical Cigarettes. Nicotine Tob Res 18:524-30
Bickel, Warren K; Mellis, Alexandra M; Snider, Sarah E et al. (2016) Novel Therapeutics for Addiction: Behavioral and Neuroeconomic Approaches. Curr Treat Options Psychiatry 3:277-292
LeSage, M G; Staley, M; Muelken, P et al. (2016) Abuse liability assessment of an e-cigarette refill liquid using intracranial self-stimulation and self-administration models in rats. Drug Alcohol Depend 168:76-88
Adkison, Sarah E; Bansal-Travers, Maansi; Rees, Vaughan W et al. (2016) Application of the Smokeless Tobacco Expectancies Questionnaire to Snus. Am J Health Behav 40:652-8
Zhao, Tingting; Luo, Xianghua; Chu, Haitao et al. (2016) A two-part mixed effects model for cigarette purchase task data. J Exp Anal Behav 106:242-253
Ho, Yen-Yi; Starr, Timothy K; LaRue, Rebecca S et al. (2016) Case-oriented pathways analysis in pancreatic adenocarcinoma using data from a sleeping beauty transposon mutagenesis screen. BMC Med Genomics 9:16

Showing the most recent 10 out of 31 publications